cd19/cd20/bcma car t cells
Non-Hodgkin Lymphoma, B-cell
Shanghai Cell Therapy Group Co.,LtdCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Non-Hodgkin Lymphoma, B-cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
men1703 Ryvu Therapeutics SA | Phase 2 | CCC |
hem101 National Research Center for Hematology, Russia | Phase 1/2 | CCC |
Sctb35 Sinocelltech Ltd. | Phase 1 | CC |
Bcma Car T Cells Shanghai Cell Therapy Group Co.,Ltd | Early Phase 1 | C |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →